Published in Vaccine Weekly, August 5th, 1996
BEC-2 is a proprietary anti-idiotypic monoclonal antibody designed to mimic GD3, a glycolipid (ganglioside) antigen which is found on the surface of a number of tumor cells, including small cell lung cancer (SCLC), melanoma and a variety of soft tissue sarcomas, and is intended to elicit a cancer-fighting immune response in patients with these tumor cells. BEC-2 works by inducing an immune response against the GD3 ganglioside.
On May 20, 1996, at the Annual Meeting of the 32nd...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.